Papatheodoridi M. Rates and predictors of HBsAg loss after discontinuation of effective long-term Entecavir or Tenofovir therapy in non-cirrhotic HBeAg-negative Chronic Hepatitis B patients: Results from the DARING-B prospective Greek study. PS-159.
Stoppen met nucleos(t)ide-analogen bij HBeAg-negatieve chronische hepatitis B?
aug 2023 | Hepatitis, Hepatologie